Cryopreservation of human hematopoietic stem and progenitor cells loaded with trehalose: Transient permeabilization via the adenosine triphosphate-dependent P2Z receptor channel by Buchanan, Sandhya S. et al.
Louisiana State University 
LSU Digital Commons 
Faculty Publications Department of Biological Sciences 
12-1-2005 
Cryopreservation of human hematopoietic stem and progenitor 
cells loaded with trehalose: Transient permeabilization via the 
adenosine triphosphate-dependent P2Z receptor channel 
Sandhya S. Buchanan 
University of Colorado Denver 
Michael A. Menze 
Louisiana State University 
Steven C. Hand 
Louisiana State University 
David W. Pyatt 
Summit Toxicology 
John F. Carpenter 
University of Colorado Denver 
Follow this and additional works at: https://digitalcommons.lsu.edu/biosci_pubs 
Recommended Citation 
Buchanan, S., Menze, M., Hand, S., Pyatt, D., & Carpenter, J. (2005). Cryopreservation of human 
hematopoietic stem and progenitor cells loaded with trehalose: Transient permeabilization via the 
adenosine triphosphate-dependent P2Z receptor channel. Cell Preservation Technology, 3 (4), 212-222. 
https://doi.org/10.1089/cpt.2005.3.212 
This Article is brought to you for free and open access by the Department of Biological Sciences at LSU Digital 
Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Digital 
Commons. For more information, please contact ir@lsu.edu. 
University of Louisville
From the SelectedWorks of Michael A. Menze
Winter 2005
Cryopreservation of Human Hematopoietic Stem
and Progenitor Cells Loaded with Trehalose:
Transient Permeabilization via the Adenosine
TriphosphateDependent P2Z Receptor Channel
Sandhya S. Buchanan







Volume 3, Number 4, 2005
© Mary Ann Liebert, Inc.
Frontiers in Clinical Research
Cryopreservation of Human Hematopoietic Stem and
Progenitor Cells Loaded with Trehalose: Transient
Permeabilization via the Adenosine Triphosphate-
Dependent P2Z Receptor Channel
SANDHYA S. BUCHANAN,1 MICHAEL A. MENZE,2 STEVEN C. HAND,2
DAVID W. PYATT,3 and JOHN F. CARPENTER1
ABSTRACT
Hematopoietic stem and progenitor cells (HPCs) are a heterogenic population of cells used to treat a number of
human diseases. Multilineage differentiation is a required function in successful hematopoietic reconstitution af-
ter transplantation of cryopreserved grafts. Conventional use of the cryoprotectant dimethyl sulfoxide (DMSO)
has resulted in some reports of infusion related toxicity attributed to DMSO and/or damage to cells during freeze-
thawing procedures. The purpose of this study was to explore the use of trehalose, a nontoxic disaccharide of glu-
cose, as an alternative cryoprotectant. Trehalose was introduced into HPCs using the P2Z receptor, known to form
nonselective pores in the presence of extracellular adenosine 5-triphosphate (ATP4). Cells loaded with trehalose
were frozen and stored at 80°C for 4 months. After storage, cells were thawed and evaluated for differentiation
capacity and clonogenic output. Results obtained with this technique were compared to traditional freezing pro-
tocols using 10% (v/v) DMSO. Clonogenic output of cells frozen with trehalose was approximately 90% of that of
unfrozen control cells. Furthermore, there were no significant alterations in phenotypic markers of differentia-
tion, activation, and proliferation. These data demonstrate that preservation of HPC function with trehalose is su-
perior to that obtained with DMSO and this method could be widely adapted to any cell or tissue type express-
ing the P2Z receptor. Furthermore, cells loaded with trehalose can potentially be freeze-dried for storage at ambient
temperatures.
INTRODUCTION
THE THERAPEUTIC USE of hematopoietic stemand progenitor cells (HPCs) to treat a vari-
ety of human diseases, has led to a critical need
for more effective cryopreservation proce-
dures.1 These freeze-thawing protocols for all
clinically relevant cellular products must not
only result in high recoveries (e.g., 90%) of
viable, functional cells but also must be de-
signed to minimize adverse responses in pa-
tients. Currently, HPCs are cryopreserved in
high concentrations (e.g., 1–2 M) of dimethyl
sulfoxide (DMSO).2,3 Cell preparations are then
1Center for Pharmaceutical Biotechnology and Department of Pharmaceutical Sciences, University of Colorado at
Denver and Health Sciences Center, Denver, Colorado.
2Division of Cellular, Developmental and Integrative Biology, Department of Biological Sciences, Louisiana State
University, Baton Rouge, Louisiana.
3Summit Toxicology, Lafayette, Colorado.
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thawed and can be transfused directly into a
patient without removing the DMSO, which is
a likely cause of adverse effects and toxicity.4–6
Efforts to improve safety measures include
DMSO removal prior to transfusion by time-
consuming wash protocols, which can result in
decreased recovery of viable cells.2–4,7,8 Be-
cause the absolute number of HPCs is the best
predictor of the clinical efficacy of the graft,9
reduction in cell recoveries can affect patient
outcomes. Therefore, an effective nontoxic cry-
oprotectant, which does not need to be re-
moved from the graft prior to transfusion,
would be of significant clinical benefit.
Cell membranes are impermeable to many
nontoxic alternative cryoprotectants (e.g., su-
crose or trehalose), and therefore the intracel-
lular concentrations required for effective cry-
opreservation usually cannot be achieved.
Several approaches have been developed to in-
crease the levels of intracellular trehalose in-
cluding molecular engineering,10 manipulating
lipid phase transitions,11 and fluid phase en-
docytosis.12 Toner and colleagues have devel-
oped an innovative approach that uses a ge-
netically engineered -hemolysin derived from
Staphylococcus aureus to permeabilize mam-
malian cells to compounds such as sucrose or
trehalose.13,14 Eroglu et al.14 used this approach
to introduce trehalose to human keratinocytes
for the purpose of cryopreservation. This
method was then used to develop a novel po-
ration technique and cryopreservation method
for HPCs using trehalose.15 Colony-forming
units (CFUs) generated from cells frozen and
thawed with intra-cellular and extracellular
trehalose were essentially equivalent in size,
morphology, and number to those generated
by unfrozen control cells. Additionally, there
were no observable alterations in phenotypic
markers of differentiation. Taken together, the
studies with the exogenous pore protein pro-
vide “proof-of-principal” data for the general
utility of using transient poration of cell mem-
branes to increase the levels of disaccharide
cryoprotectants inside cells.
Although the use of an exogenous, bacteria-
derived pore protein would allow effective per-
meabilization and cryopreservation of various
cell types, it would be necessary to remove the
pore protein prior to clinical use to avoid a po-
tential adverse immunological response in pa-
tients. In the current study we have investi-
gated permeabilization of cells to trehalose
with an endogenous cell surface receptor,
termed P2Z16,17 (synonymous with P2X7).18 In
the presence of millimolar concentrations of ex-
tracellular adenosine triphosphate (ATP), this
protein forms an indiscriminate pore that ren-
ders the plasma membrane permeable to small
molecules (e.g., molecular weight [MW]  900
Da).19,21 Addition of magnesium to complex
with the ATP reverses this effect, so that cells
can be permeabilized transiently.22 Indeed,
membrane-impermeant metabolic effectors
have been loaded into J774 macrophages via
the P2Z channel with retention of high cellular
viability23,24 as well as large quantities of tre-
halose (G. Elliot, J. Cusick, M.A. Menze, T. Witt,
S.C. Hand, and M. Toner, unpublished obser-
vations).
P2Z is expressed in many hematopoietic cells
including myeloid progenitors, CD34 periph-
eral blood progenitor cells as well as mature
cell types such as granulocytes, neutrophils,
monocytes/macrophages, lymphocytes, den-
dritic, and erythrocytes.19,25–27 In the current
study, we used a model cell line for HPCs (TF-
1 cells) that we determined expresses the P2Z
receptor. TF-1 cells are cytokine-dependent,
CD34-positive, and retain the ability to differ-
entiate in culture down erythroid, monocytic,
and megakaryocytic lineages after proper stim-
ulation.28 These characteristics make TF-1 cells
an appropriate surrogate for primary experi-
ments designed to evaluate the effects of P2Z
receptor-mediated permeabilization and cry-




TF-1 cells (cell line: CRL-2003; American Tis-
sue Culture Collection, Manassas, VA) were
cultured in RPMI complete medium (RPMI
1640, 2 mM L-glutamine, 5 mM glucose, 10 mM
HEPES, 10 mM penicillin, 10 mM streptomycin,
10% fetal bovine serum [FBS], bovine serum al-
bumin [BSA], 1 mM sodium pyruvate and 2
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ng/mL granulocyte-macrophage colony-stim-
ulating factor [GM-CSF; University Hospital
Pharmacy, Denver, CO]. Culture medium was
changed every 2 days; after centrifugation and
the removal of old media. Growing cells were
resuspended at a density of 2–3  105
cells/mL. Cells used for permeability studies
were between passage 2 and 12 and cells used
for cryopreservation studies were between pas-
sage 2 and 9. The cells were discarded after the
twelfth passage.
Expression of P2Z receptor on TF-1 cells
Expression of P2Z receptor was measured by
permeabilizing TF-1 cells with BD Cytofix/Cy-
toperm kit (BD Biosciences Pharmingen, San
Diego, CA) using manufacturer’s instructions,
staining with anti-P2Z/P2X7 receptor (Cal-
biochem, La Jolla, CA) polyclonal antibody
from rabbit and anti-rabbit-PE secondary anti-
body developed in goat (Sigma, St. Louis, MO).
Briefly, 1  106 TF-1 cells were washed twice
with 1 mL of staining buffer (phosphate-
buffered saline [PBS]/1% FBS/0.05% [w/v]
sodium azide). Cells were pelleted by centrifu-
gation (1100 rpm for 8 min) and then resuspend
in 250 L of BD Cytofix/Cytoperm solution for
30 min at 4°C to fix cells. Cells were washed
twice in 1 mL of 1 BD Perm/Wash solution.
Cells were then thoroughly resuspended in 50
L of BD Perm/Wash solution containing anti-
P2Z/P2X7 (1:100) for 30 min at 4°C. Cells were
washed twice in 1 mL of 1 BD Perm/Wash
solution. Cells were then resuspended in 50 L
of 1 BD Perm/Wash solution containing 20
L of anti-rabbit-PE for 30 minutes at 4°C in
the dark. Cells were washed twice in 1 mL
staining buffer. Cells were then resuspended in
300 L of staining buffer and stored at 4°C in
the dark until flow cytometric analysis. Flow
cytometric analysis was performed with a
Coulter FC500 equipped with CXP software.
Poration efficiency
TF-1 cells were harvested in the log phase of
growth following standard methods. TF-1 cells
were incubated in poration buffer (5 mM glu-
cose, 1 essential amino acids, 1 nonessen-
tial amino acids, and 1 Vita Stock at pH 7.45
[modified from Menze et al.23]) containing 5
mM ATP, 200 mM trehalose, and 100 L of flu-
orescein isothiocyanate (FITC; 0.1 mg/mL).
FITC is an impermeable fluorescent dye used
to quantitate poration efficiency. Pores were
closed with the addition of 1 mM MgSO4 and
10-fold dilution of ATP using RPMI. Each sam-
ple contained 1  106 cells in 1 mL of porating
buffer. Control cells were treated in an identi-
cal manner without the addition of ATP.
After poration and trehalose loading, TF-1
cells were washed twice with PBS/5% FBS and
resuspended in 500 L of PBS/1% FBS con-
taining 10 L of PI (1 mg/mL). Samples were
analyzed for viability in addition to the pres-
ence and intensity of FITC using a Coulter
Epics XL flow cytometer equipped with Sys-
tem II software.
Determination of optimal processing conditions
Optimal processing conditions were first es-
tablished by determining the trehalose-loading
concentration offering the highest CFU after
freeze-thawing. TF-1 cells were incubated in
the presence of increasing concentrations of tre-
halose (0–600 mM) for 60 min at 37°C with 5
mM ATP. Control cells were incubated under
the same conditions without trehalose. Sam-
ples were placed in Nalgene cryotubes and
frozen in complete medium containing either
the same trehalose concentration as the pora-
tion condition or in 10% (vol/vol) DMSO (1.4
M) and 0.025% of human serum albumin
(HSA). Cryotubes were transferred to a Nal-
gene cryogenic controlled-rate freezing con-
tainer (Fisher Scientific, Atlanta, GA). It was
placed in a 80°C freezer, and stored there for
4 months at 80°C. Frozen cells were rapidly
thawed in a 37°C water bath and allowed to
rest for 1 h at room temperature in laminar-
flow hood. Function of TF-1 cells after freeze-
thawing was determined by CFU assay. Con-
trol cells frozen in DMSO were transferred
directly to methylcellulose (final DMSO con-
centration was 0.2% [vol/vol]).
To ascertain the efficacy of trehalose as a cry-
oprotectant, cells were frozen with the deter-
mined optimal trehalose concentration in a fi-
nal volume of 1 mL RPMI/20% FBS under one
of the following experimental conditions: ex-
tracellular trehalose (200 mM), intracellular
BUCHANAN ET AL.214
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trehalose (200 mM in porating buffer), and in-
tra/extracellular trehalose (200 mM). Function
of TF-1 cells after freeze-thawing was deter-
mined by CFU assay.
Colony-forming unit assay
Progenitor cell proliferation of thawed cells
was detected by an established in vitro method
using a semisolid methylcellulose system
(StemCell Technologies, Vancouver, British
Columbia, Canada) measuring clonogenic out-
put via CFU. Frozen TF-1 cells were rapidly
thawed (37°C water bath), counted, and ap-
proximately 2  103 cells/mL were transferred
to methylcellulose. Freshly cultured, unfrozen
cells served as positive controls. All samples
were established with quadruplicate plates
and cultured at 37°C in humidified air con-
taining 5% CO2 for 14 days, after which
colonies were enumerated on an inverted
Nikon microscope (1 colony contains a mini-
mum of 50 cells).
Viability assays
Cells were assayed for viability by trypan
blue (TB) exclusion or flow cytometric analysis
using propidium iodide (PI). For TB exclusion,
100 L of cells were diluted 1:5 (100 L cells:100
L TB:300 L PBS). Cells negative for TB were
considered live and those that stained blue
were considered dead. Cell viability/poration
efficiency was assessed by FITC/PI staining us-
ing flow cytometry. Briefly, porated cells were
loaded with trehalose and FITC. Pores were
closed and excess dye was removed by wash-
ing twice with PBS/1% FBS. Subsequently, 1 
105 porated cells were removed and suspended
in 500 L of PBS/1% FBS. After pores were
closed, cellular viability was monitored using
a membrane-impermeant dye, PI, which labels
the nucleic acids of membrane-compromised
cells. Cells were treated with 10 L of 1.0
mg/mL PI for 4 min prior to analysis. Cells that
stained positive for FITC and negative for PI
were gated and considered to be both viable
and porated, whereas cells stained with PI were
gated as dead. All reported viability was nor-
malized to total cell count. Flow cytometric
analysis was performed on a Coulter Epics XL
equipped with System II software.
Phenotypic analysis of surface antigens
After poration, experimental cells were
stained with a cocktail of three monoclonal an-
tibodies (mAb) conjugated to three discrete flu-
orophores: CD34-PerCp, CD38-PE, and CD71-
FITC (BD Biosciences Pharmingen). Additional
fluorophores investigated were CD33-PE and
CD235a-PE (glycophorin A). Approximately
1  105 porated cells were incubated with the
antibody cocktail for 30 min at 4°C, washed
twice with PBS/5% FBS, and resuspended in
PBS/1% FBS. Following standard flow cyto-
metric protocols, three-color analysis analyses
of these three phenotypic markers was con-
ducted simultaneously with a Coulter Epics XL
equipped with System II software. The isotype
controls IgG-PerCp, IgG-PE, and IgG-FITC
were also purchased from BD Biosciences
Pharmingen.
Statistical analysis
Statistical analysis was performed on viabil-
ity, immunophenotype and CFU assay results
using student SigmaPlot 2001. Differences
among groups were considered significant
when p values were less than 0.05. CFU exper-
iments were repeated three times with qua-
druplicates. Poration efficiency, viability, and
immunophenotype were repeated three times
with triplicates. Data reported are means of
survival rates representing the standard devi-
ation from the mean.
RESULTS AND DISCUSSION
Expression of P2ZR and permeabilization 
of TF-1 cells
We investigated the expression of P2Z re-
ceptor on TF-1 cells using indirect staining and
flow cytometric analysis (Fig. 1). Staining with
secondary antibody alone marked the back-
ground fluorescence level by nonspecific bind-
ing of this antibody to dead or other cells
(1.1%  0.3%, Fig. 1A). Fluorescence levels
above the background were considered spe-
cific for P2Z and shown to be approximately
86%  5% (Fig. 1B) compared to secondary an-
tibody alone (overlay of A and B as shown in
Fig. 1C).
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Experimental conditions are critically im-
portant to allow effective transfer of solute
into the cells, and ensure maintenance of cell
viability. These parameters were optimized by
using dye uptake to characterize permeabi-
lization. FITC was used as an indicator of po-
ration because it is impermeable to cellular
membranes and has a similar molecular mass
(MW 389) to that of trehalose (MW 342). As
shown in Figure 1D (solid circles), as a func-
tion of permeabilization time (up to 40 min),
there was a monotonic increase in the number
of cells containing FTIC. After 40 min, the in-
crease in dye uptake slowed greatly. After 60
min of permeabilization, 87% of the cells were
positive for FITC, consistent within error, with
the percentage of cells expressing P2Z recep-
tor. Less than 2% of cells incubated at 37°C in
the absence of ATP displayed dye uptake, in-
dicating that permeabilization is dependent
upon P2Z receptor-associated pore formation.
After 60 min of poration, 88  3% of the cells
remained viable (Fig. 1D, open squares), com-
parable to viability in untreated control cells
(91%  2%). These results indicate that TF-1
cells can be reversibly permeabilized via P2Z
receptor without a significant decrease in cell
viability.
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FIG. 1. Expression of P2Z receptor and dye uptake by porated TF-1 cells. Expression of P2Z receptor was measured
by immunofluorescence and analyzed by flow cytometry. (A) Negative control by treatment with secondary antibody
alone signifying nonspecific binding or background fluorescence (approximately 1.1%). (B) Cells stained with anti-
P2Z showed approximately 86% of TF-1 cells express the P2Z receptor compared to control cells. (C) Overlay of (A)
and (B) showing comparison of background fluorescence to cells positive for P2Z. (D) Dye uptake and viability of
porated TF-1 cells. Dye uptake (closed circles) during permeabilization was measured by determining fluorescein
isothiocyanate (FITC)-positive cells with flow cytometry. Viability of porated cells (open squares) was measured by
quantifying propidium iodide-negative cells with flow cytometry. Dye uptake and viability values are represented
as the mean  standard deviation of three independent experiments, each with triplicate samples.
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Determination of optimal processing conditions
for cryopreserving with trehalose
To investigate the effect of trehalose concen-
tration on post-poration viability, TF-1 cells
were incubated in poration buffer containing
increasing concentrations of trehalose (0–800
mM) for 60 min after which pores were closed
as described above. Cells incubated without
trehalose were 65% viable after this treatment,
(Fig. 2). Cells treated in the presence 50–200
mM trehalose exhibited the highest postpora-
tion viability. At higher concentrations of tre-
halose, viability decreased with increasing con-
centrations of trehalose.
To optimize duration of permeabilization
and trehalose concentration for cryopreserva-
tion, TF-1 cells were permeabilized in the pres-
ence of 0–600 mM trehalose for 0–90 min. Af-
ter closing pores, cells were frozen in the same
trehalose concentrations used for poration. The
viability and function of thawed cells were as-
sessed by measuring clonogenic output. For
these experiments, cells were transferred di-
rectly from the cryopreservation solution into
methylcellulose, without dilution or washing
steps. The clonogenic potential of treated cells
was compared to untreated cells (Fig. 3). Po-
rated cells frozen in the absence of trehalose
did not produce any colonies, documenting
that a cryoprotectant is required to maintain
cell viability during freeze-thawing. There was
wide range in the recoveries in samples treated
with trehalose, which depended on both the
concentration of trehalose and the duration of
permeabilization prior to freezing. The great-
est clonogenic output (approximately 90% of
control) was observed with HPC porated in the
presence of 200 mM trehalose for 60 min and
frozen in a 200 mM trehalose solution. The level
of cell survival during freeze-thawing approx-
imates the percentages of cells that could be
permeabilized via P2Z receptor, suggesting
that P2Z positive cells survived freeze-thaw.
In contrast, cells frozen and thawed in 10%
DMSO generated 70% of the colonies pro-
duced by untreated control cells. Previous re-
sults from our laboratory indicated that ap-
proximately 100% of clonogenic output was
maintained during freezing and thawing in
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FIG. 2. Optimal trehalose concentration for poration. TF-1 cells were porated in the presence of increasing con-
centrations of trehalose (0–800 mM) and incubated for 60 min. Viability was determined by trypan blue exclusion.
All values are represented as the mean  standard deviation for three independent experiments, each with tripli-
cate samples.
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10% DMSO. The freeze-thawing protocols
were identical in both studies, but in the ear-
lier studies the DMSO was washed out from
cells prior to CFU assay. In the current study,
the cells were directly transferred from the
DMSO solution into methylcellulose, which
likely resulted in the observed reduction in cell
viability.
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FIG. 3. Determination of optimal processing conditions by colony-forming units (CFU) of TF-1 cells. TF-1 cells were
porated cells in the presence of trehalose (0–600 mM) for 0–90 min, frozen, and stored at 80°C for 4 months. Cells
were rapidly thawed at 37°C and then transferred into methylcellulose. CFU produced by experimental cells were
compared to CFU produced by untreated cells (100%, solid circle, n  12) and cells frozen in dimethyl sulfoxide
(DMSO) (68%, open circle). The optimal processing conditions were observed with 200 mM trehalose (open triangles,
91%).
FIG. 4. Effects of intracellular and extracellular trehalose of TF-1 cells during freeze-thawing. TF-1 cells were po-
rated in the presence of 200 mM trehalose for 60 min. One set of samples were frozen immediately with both intra-
cellular and extracellular trehalose. In another set the extracellular trehalose was removed prior to freezing. To a third
set of samples of cells, which were not porated, 200 mM extracellular trehalose was added prior to freezing. The
frozen samples were stored at 80°C, rapidly thawed, and assayed for colony-forming units (CFU).
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Effects of intracellular and extracellular trehalose
of TF-1 cells during freeze-thawing
An important consideration for developing
cryopreservation protocols for HPC is whether
effective cryoprotection requires the cryopro-
tecting compound to be intracellular, extracel-
lular or both. If only an extracellular cryopro-
tectant was required, then a permeabilization
step would be unnecessary. To address this is-
sue, TF-1 cells were porated via P2Z receptor
using optimal conditions (i.e., in the presence
of 200 mM trehalose for 60 min). After closing
the pores, cells were frozen in the presence of
both intracellular and extracellular trehalose,
or after the extracellular trehalose had been
washed away (Fig. 4). Unporated cells were
frozen with 200 mM extracellular trehalose. All
samples were stored at 80°C, as a test of stor-
age stability, for 4 months before thawing. As
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FIG. 5. Evaluation of immunophenotype of TF-1 cells by direct immunofluorescence and flow cytometry. Pheno-
typic markers were measured in untreated TF-1 cells, after poration, and after freeze-thawing. Makers for differenti-
ation, activation, and proliferation were assessed (see text). Untreated TF-1 cells were positive for CD33, CD34, CD38,
CD71, and negative for CD235a. There were no significant alterations in phenotypic markers following poration or
freeze-thawing. All values are represented as the mean  standard deviation of three independent experiments each
with quadruplicate samples.
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shown in Figure 4, both intracellular and ex-
tracellular trehalose were needed to maximize
cryopreservation of TF-1 cells.
These results demonstrate that trehalose is
required on both sides of the plasma membrane
to protect it from damage, as well as in the cy-
toplasm to stabilize intracellular components
during freeze-thawing. Previous studies by
Crowe and colleagues demonstrated that tre-
halose present on both sides of isolated mem-
brane vesicles and yeast membrane bilayers not
only maximizes protection during freezing but
also during desiccation.29–32 It is possible that
trehalose on both sides of the plasma mem-
brane, as well as in the cytoplasm may not only
prevent damage to the membrane and intra-
cellular components during freeze-thawing,
but may also afford protection for HPC sur-
vival in a desiccated state.
Effect of poration and freeze-thawing on
immunophenotype
To investigate if poration and freeze-thaw-
ing alter phenotypic makers of differentiation,
activation and proliferation, we performed
immnuophenotypic analysis33 by flow cytom-
etry. Markers chosen for this step were CD34,
CD33, CD38, CD71, and CD235a. CD34 expres-
sion is highest in relatively immature hemato-
poietic stem and progenitor cells and is often
used to select cells with the hematopoietic 
potential required for hematopoietic reconsti-
tution. CD38 can be used as an activation
marker for proliferating cells and CD33 is an
early myeloid marker. CD71 expression, the
transferrin receptor, can be used to study cells
in transition from resting to a proliferative
state. CD235a (glycophorin A) is expressed 
on human red blood cells and erythroid pre-
cursor cells. At baseline, untreated TF-1 cells
were shown to express CD34, CD33, CD38,
CD71 but not CD235a (Fig. 5A). The relative
levels of these antigens document that TF-1
cells are hematopoietic and myeloid progeni-
tors 1(CD34 and CD33), activated (CD38),
highly proliferative (CD71), but are CD235a
negative. After 60 min permeabilization in 
the presence of 200 mM trehalose, pores were
closed and reanalyzed immediately after por-
ation and after freeze-thawing (Fig. 5B). The 
expression levels of phenotypic markers, as
measured with flow cytometry, demonstrate
that cell activation, proliferative status, and 
differentiation were not significantly altered
following P2Z receptor activation, loading of
intracellular trehalose, and freeze-thawing com-
pared to untreated control.
Potential application of poration via the P2Z
receptor to cryopreservation of other cell types
Expression and activation of the P2Z recep-
tor has also been investigated in nonhemato-
poietic tissue. A study by Collo et al.19 demon-
strates that the P2Z receptor present in the
brain are expressed by microglia and ependy-
mal cells rather than neurons. Since microglia
are the resident macrophages of the brain, it is
consistent with the finding of P2Z receptor in
peripheral macrophages and macrophage-like
cells found in the lung and spleen.18 This re-
ceptor has also been described in primary hu-
man cells such as fibroblasts,34 fetal keratino-
cytes,35 vascular endothelial cells,36 and vein
smooth muscle.37 Cells derived from rodents,
such as astrocytes, medulla oblongata,38 parotid
acinar cells,39 and spinal cord cells38 along with
immortal microglial,40 CHO-K1,40 and mesan-
gial cells19 have also been permeabilized with
P2Z receptor. With such a wide range of cells
already known to express this protein, there 
is potentially a wide application of cryopre-
serving a variety cells with trehalose using 
this method and development in freeze-drying
applications.
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